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A review of the whole literature shows that the drug is bactericidal by some adjuvant factors [Nitti, Bovet and Depierre (1937) , FinklestoneSayliss, Paine and Patrick (1937) , Lockwood (1938) (1938) , Weld and Mitchell (1939) ]. The observation of Britton (1938) , that it is active against pneumococcus type I in peptonecontaining broth but practically inactive in vivo, makes the problem more complex.
One of the necessary conditions for its therapeutic action is that the organism and the drug should actually meet in the body of the host (Browning, 1939) (Mcintosh and Whitby, 1939 (Browning, 1939 (Shaffer, 1939 (Wendel, 1938, Bensley and Wilen, 1939 Wendel (1938) ] and occasionally with that of sulphsemoglobin (Colebrook and Purdie, 1937) . Marshall and Walzal (1937) , however, suggest that the cyanosis may not be due to any change in the condition of the blood pigment but may be due to the formation of an oxidation product of sulphanilamide (Ottenberg and Fox, 1938) . The observations of Harris and Michel (1939) that the intensity of methsemoglobinsemia is proportional to the concentration of the drug, tends to show that the methsemoglobin formation during treatment is a definite action of the drug. Sulphanilamide itself cannot oxidize hsemoglobin in vitro, whereas in contact with body tissues it undergoes a change that is responsible for the production of methsemoglobin (Harris, 1939 [June, 1940 in vitro (McEllroy, 1919, Scott and Hanzlik, 1920) . Considerable differences of opinion exist regarding its mechanism, but the general belief now is that p-amino phenol formed in the system from the above aniline bodies is mainly responsible for this cyanosis [Heubner and Schwedtke (1936) , Schwedtke (1938) 
In in vitro experiments sulphanilamide can be oxidized to quinone (III), when it would not be unreasonable to expect that an oxidation in in vivo may lead at least to the formation of p-iminoquinone (II) . If this latter product be once formed in the body, it would establish an oxidation-reduction equilibrium with p-aminophenol (I) and, as such, may be the cause of the oxidation of hsemoglobin to methsemoglobin (Rimington, 1939) . On this basis, the formation of methsemoglobin would first depend on the ease of oxidation of sulphanilamide drugs to p-iminoquinone. In clinical practice, too, the rate of formation of methsemoglobin is found to be much lower in 2-(p-aminobenzene sulphonamido) -pyridine (IV) and p-benzylamino benzene sulphonamide (V), two products less susceptible to decomposition from chemical consideration [Harris and Michel (1939) , Finland (1939) ]. Acidosis, by interfering with absorption of alkalis in renal tubes, and an increase in the urinary excretion of porphyrin, are two other common physiological disorders during this chemotherapeutic treatment (Rimington and Hemmings, 1938 (Wendel, 1939) . This seems to be logical as this readily reducible dye, by disturbing the reversible reduction-oxidation equilibrium between the above two agents, would then inhibit the formation of any further quantity of methsemoglobin. Any conjugation of sulphanilamide would make it more resistant to oxidation and this would in turn lessen the probability of any change in the haemoglobin molecule. Such a conjugation has been actually found by Bensley (1940) to reduce the formation of methsemoglobin. All these then point to an alteration in the composition of sulphanilamide in the body. Further, the fact that the concentration of both free and acetylated sulphanilamide is invariably higher in the corpuscles than in the plasma, again indicates an existence of a close relationship between blood corpuscle and sulphanilamide (Hansen, 1939 It would be of much interest to study the exact chemical nature of the drug that is being daily excreted in the urine, circulated in the blood and more particularly remaining associated with the red blood corpuscles. The next point of importance seems to be study on the effect of the drug on endotoxin in vitro in the presence of several body tissues under various conditions, and then to note the effect of such a mixture on treated and untreated animals.
An investigation on the change, if any, in the constitution of the drug seems also to be essential. All these might bring forth a clue to the mechanism by which this group of drugs exert their characteristic pharmacological action, or, at least might throw light on the problem whether the oxidant that is invariably formed, exerts any influence on the anti-bacterial action of the drug. For such a study team work from
